http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 May 2026 08:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a <span>Master Cell Bank</span> (MCB) of genetically modified cells that overexpress the α-Klotho protein.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Complete+GMP+Master+Cell+Bank%2C+Begin+Viral+Testing+for+Cell-Based+Klotho+Anti-Aging+Therapy/26525516.html Wed, 20 May 2026 08:45:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AVAI+BIO%2C+INC.++++++++++++For%3A+May+07/26461342.html si-local-file:///var/storage/secattach/20260508/26461342.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AVAI+BIO%2C+INC.++++++++++++For%3A+May+07/26461342.html Fri, 08 May 2026 16:16:00 -0400 AVAI O.41514066 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AVAI+BIO%2C+INC.++++++++++++For%3A+May+07/26461342.html si-local-file:///var/storage/secattach/20260508/26461342.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AVAI+BIO%2C+INC.++++++++++++For%3A+May+07/26461342.html Fri, 08 May 2026 16:16:00 -0400 AVAI O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>April 7, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual <span>Klotho Conference</span>, which focuses on the future of Klotho-based therapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html Tue, 07 Apr 2026 08:00:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>April 7, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual <span>Klotho Conference</span>, which focuses on the future of Klotho-based therapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html Tue, 07 Apr 2026 08:00:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>April 7, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual <span>Klotho Conference</span>, which focuses on the future of Klotho-based therapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html Tue, 07 Apr 2026 08:00:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>April 7, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual <span>Klotho Conference</span>, which focuses on the future of Klotho-based therapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html Tue, 07 Apr 2026 08:00:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>April 7, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual <span>Klotho Conference</span>, which focuses on the future of Klotho-based therapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html Tue, 07 Apr 2026 08:00:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>April 7, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual <span>Klotho Conference</span>, which focuses on the future of Klotho-based therapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html Tue, 07 Apr 2026 08:00:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>April 7, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual <span>Klotho Conference</span>, which focuses on the future of Klotho-based therapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html Tue, 07 Apr 2026 08:00:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>April 7, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual <span>Klotho Conference</span>, which focuses on the future of Klotho-based therapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+to+Present+Latest+Data+on+Klotho+Anti-Aging+Therapy+at+Annual+Klotho+Conference/26280541.html Tue, 07 Apr 2026 08:00:00 -0400 A.50211433 AVAI O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova—the initiation of production for a <span>Master Cell Bank</span> of genetically modified cells that overexpress the α-Klotho protein. </p> <p>These cells will enable Klothonova, the parties' joint venture (JV), to advance its anti-aging product candidate within the ongoing α-Klotho development program, following the successful completion of all preparatory activities in February.</p><p>This milestone supports the JV's http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html Tue, 03 Mar 2026 08:30:00 -0400 A.50208593 A.50211433 AVAI O.00303771 O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova—the initiation of production for a <span>Master Cell Bank</span> of genetically modified cells that overexpress the α-Klotho protein. </p> <p>These cells will enable Klothonova, the parties' joint venture (JV), to advance its anti-aging product candidate within the ongoing α-Klotho development program, following the successful completion of all preparatory activities in February.</p><p>This milestone supports the JV's http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html Tue, 03 Mar 2026 08:30:00 -0400 A.50208593 A.50211433 AVAI O.00303771 O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova—the initiation of production for a <span>Master Cell Bank</span> of genetically modified cells that overexpress the α-Klotho protein. </p> <p>These cells will enable Klothonova, the parties' joint venture (JV), to advance its anti-aging product candidate within the ongoing α-Klotho development program, following the successful completion of all preparatory activities in February.</p><p>This milestone supports the JV's http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html Tue, 03 Mar 2026 08:30:00 -0400 A.50208593 A.50211433 AVAI O.00303771 O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova—the initiation of production for a <span>Master Cell Bank</span> of genetically modified cells that overexpress the α-Klotho protein. </p> <p>These cells will enable Klothonova, the parties' joint venture (JV), to advance its anti-aging product candidate within the ongoing α-Klotho development program, following the successful completion of all preparatory activities in February.</p><p>This milestone supports the JV's http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html Tue, 03 Mar 2026 08:30:00 -0400 A.50208593 A.50211433 AVAI O.00303771 O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova—the initiation of production for a <span>Master Cell Bank</span> of genetically modified cells that overexpress the α-Klotho protein. </p> <p>These cells will enable Klothonova, the parties' joint venture (JV), to advance its anti-aging product candidate within the ongoing α-Klotho development program, following the successful completion of all preparatory activities in February.</p><p>This milestone supports the JV's http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html Tue, 03 Mar 2026 08:30:00 -0400 A.50208593 A.50211433 AVAI O.00303771 O.17509382 O.41514066 http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova—the initiation of production for a <span>Master Cell Bank</span> of genetically modified cells that overexpress the α-Klotho protein. </p> <p>These cells will enable Klothonova, the parties' joint venture (JV), to advance its anti-aging product candidate within the ongoing α-Klotho development program, following the successful completion of all preparatory activities in February.</p><p>This milestone supports the JV's http://www.streetinsider.com/Press+Releases/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html Tue, 03 Mar 2026 08:30:00 -0400 A.50208593 A.50211433 AVAI O.00303771 O.17509382 O.41514066 http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- Avaí <span>Bio, Inc.</span> (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova—the initiation of production for a <span>Master Cell Bank</span> of genetically modified cells that overexpress the α-Klotho protein. </p> <p>These cells will enable Klothonova, the parties' joint venture (JV), to advance its anti-aging product candidate within the ongoing α-Klotho development program, following the successful completion of all preparatory activities in February.</p><p>This milestone supports the JV's http://www.streetinsider.com/PRNewswire/Ava%C3%AD+Bio+and+Austrianova+Begin+Production+of+Master+Cell+Bank+for+Klotho+Anti-Aging+Therapy+Under+GMP+Standards/26097161.html Tue, 03 Mar 2026 08:30:00 -0400 A.50208593 A.50211433 AVAI O.00303771 O.17509382 O.41514066